Cord blood in regenerative medicine: do we need immune suppression? - Wikidata - wikimedia - TriplyDB

Cord blood in regenerative medicine: do we need immune suppression?

Cord blood in regenerative medicine: do we need immune suppression?

http://www.wikidata.org/entity/Q35633105

about

Stem cell therapy for autism Advancements in stem cells treatment of skeletal muscle wasting Perspectives of stem cell therapy in Duchenne muscular dystrophy Isolation and differentiation of mesenchymal stem cells from bovine umbilical cord blood.Clinical applications of mesenchymal stem cells in chronic diseases.Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions Infusion of allogeneic umbilical cord blood hematopoietic stem cells in patients with chemotherapy-related myelosuppression.Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with hereditary ataxia.Human mesenchymal stem cells - current trends and future prospective Beneficial effects of non-matched allogeneic cord blood mononuclear cells upon patients with idiopathic osteoporosis.Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-β-associated neuropathology in Alzheimer mice.Therapeutic benefit of intravenous administration of human umbilical cord blood- mononuclear cells following intracerebral hemorrhage in rat.Cord blood stem cell transplantation for haemoglobinopathies.Future of cord blood for non-oncology uses.Umbilical cord blood for cardiovascular cell therapy: from promise to fact.Autologous stem cells in neurology: is there a future?Umbilical cord blood: a trustworthy source of multipotent stem cells for regenerative medicine.Intraarterial transplantation of human umbilical cord blood mononuclear cells in hyperacute stroke improves vascular function.Dissection of the cord blood stromal component reveals predictive parameters for culture outcome.

P2860

Q24676771-78968D3C-2A77-468D-AB76-FD95555EBFA9 Q26822437-AF31FE66-EF23-4BAB-B334-1A40296CBDF2 Q27013613-EEC59717-A953-4895-91D0-8EB9752F712F Q30156920-C99AD092-7FE6-4BB3-ADFD-428A0E3C9516 Q30437823-BAAC8DE2-1A1B-4324-B022-BAC3EA50FC85 Q34067721-0AE67363-C824-4E9A-940B-AD63CD53E97F Q34445046-6D8C0455-0222-4A69-A5EC-099E8C7E0087 Q35038585-9362E2D7-09E7-44E9-A538-74AA6A5DE8E9 Q35548329-259118A1-9E5D-4575-B0A2-7190FC196B9C Q36127774-B3470619-8708-43EE-94ED-F5A4A6DF1EAC Q36547428-27C780EB-8A37-40CA-B08D-8B20E4AEA039 Q36652586-AE8EED93-76C0-4058-9883-3C46E5CE21B7 Q37096984-3A9B629E-D3F7-4360-A410-96510EDBE33C Q37607982-340FF9FB-CDF3-4625-ADC9-3E7B637ABF91 Q38006735-5CB134C0-7B8D-4843-BC82-C20F3BAFF41D Q38062482-177ABA07-0D34-472E-82DC-2851C8A55065 Q38210868-7E316C23-19C9-48A7-8D48-061BCE3B8808 Q42314752-A873926B-84E3-4520-B795-EA17F917F456 Q42552423-00C7982B-278B-4DD0-A528-E2B27E5454CB

P2860

Cord blood in regenerative medicine: do we need immune suppression?

http://www.wikidata.org/entity/Q35633105

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Cord blood in regenerative medicine: do we need immune suppression?

@ast

Cord blood in regenerative medicine: do we need immune suppression?

@en

type

label

Cord blood in regenerative medicine: do we need immune suppression?

@ast

Cord blood in regenerative medicine: do we need immune suppression?

@en

prefLabel

Cord blood in regenerative medicine: do we need immune suppression?

@ast

Cord blood in regenerative medicine: do we need immune suppression?

@en

P1433

Q35633105-9463D5BC-A0D0-4A6C-9BF2-5BEE0FEB1044

P1476

Q35633105-3D4EA620-666E-4781-B220-201BAF3F6932

P2093

Q35633105-0F284B7C-FD89-4374-B5A4-053C795F3AE6

Q35633105-4D9429F6-8812-4F0A-9DCE-79608574302E

Q35633105-7856917E-5D17-4130-8E63-4B06FB293478

Q35633105-8E403284-FA2C-4E3D-ABAE-EF9427B88762

P275

Q35633105-F8B17570-5AB4-478B-9DDB-CCB7D1F6313B

P2860

Q35633105-00391173-442D-4338-9B81-C55A97C537D4

Q35633105-00E06C01-72F4-4152-9C11-B29A2D9B79DE

Q35633105-00E60E37-A1B1-4829-931D-7FB10685B803

Q35633105-0A9FFAB9-64D8-40A0-BF26-EF727EAF8132

Q35633105-0D8CFD12-A884-4E97-B93C-5084C628EEBA

Q35633105-11D9B187-44EC-466B-A1E8-C0AD339FC8BC

Q35633105-15C9FB40-C60A-40C6-97A2-0147BD76DAEF

Q35633105-1AAD55B3-1FCD-4C8F-8C17-862C3043663D

Q35633105-1B0FEAA4-E143-4924-9A3A-21A2AD2DB47D

Q35633105-1B522E00-5E67-4B15-974B-B86B4B8F588E

P2888

Q35633105-C2DC5394-2750-43F4-9CF2-3C313A7A8AC6

P304

Q35633105-A7E8C1A7-5A84-4AAA-B212-2D5F4FCFD7C7

P31

Q35633105-244E000D-F53E-4896-B0D2-29A586A795C5

Q35633105-CA980E2F-747A-4590-BFF8-8CBFDF218F25

P356

Q35633105-23251354-91C7-4058-A562-E2D9C7158EDD

P478

Q35633105-77505E01-C472-4EBD-94F2-C5FFBB111A59

P577

Q35633105-2FF33DFB-321F-4C15-9DA2-63E979946EFB

P5875

Q35633105-4E9EEB51-F1AE-4248-BE84-A448357FB79A

P6179

Q35633105-A2BA4846-1675-467B-8D63-FE5739E9C75E

P698

Q35633105-DE77A118-41C8-4B4D-ADFE-14AC91262EDD

P921

Q35633105-3FDE5F48-8B15-44B9-99BC-8BA9F48446C3

Q35633105-67A47FDF-2BC2-4D77-A73A-4E20FDF7369A

Q35633105-69AADB11-7FE1-477B-A4D7-53258A41EE7E

Q35633105-D6E18738-8EDA-4000-8C59-1849E3F4CE85

Q35633105-DB18C99A-39E9-4A47-A59E-78C2EE2A1A46

P932

Q35633105-45CE1A4F-0398-403B-BE4B-DC33E31161DB

P356

P1433

Journal of Translational Medicine

P1476

Cord blood in regenerative medicine: do we need immune suppression?

@en

P2093

Annette M Marleau

http://www.w3.org/2001/XMLSchema#string

Kyle Chan

http://www.w3.org/2001/XMLSchema#string

Neil H Riordan

http://www.w3.org/2001/XMLSchema#string

Thomas E Ichim

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease

Transfer of fetal cells with multilineage potential to maternal tissue

A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study

Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue

Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity.

Microchimerism of presumed fetal origin in thyroid specimens from women: a case-control study.

Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms.

Umbilical cord blood stem cells can expand hematopoietic and neuroglial progenitors in vitro.

P2888

P304

8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-5-8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6543382

http://www.w3.org/2001/XMLSchema#string

P6179

1030217638

http://www.w3.org/2001/XMLSchema#string

P698

17261200

http://www.w3.org/2001/XMLSchema#string

P921

embryonic structure

maternal health

hemic and immune systems

fluids and secretions

P932

1796850

http://www.w3.org/2001/XMLSchema#string